Research Output per year
Research Outputs 2004 2019
2019
Therapeutic monitoring of TNF-alpha inhibitors in rheumatoid arthritis
Tikhonova, I., Yang, H., Salmon, A., Bello, S., Peters, J., Robinson, S., Rezaei, M., Dodman, S., Coelho, H., Kharechko, A., Haigh, R., Jani, M., McDonald, T. J., Hoyle, M. & Logan, S., 2019, University of Exeter. 425 p.Research output: Book/Report › Commissioned report › Research
Open Access
2018
Benralizumab for treating severe asthma: A Single Technology Appraisal
Tikhonova, I., Long, L., Ocean, N., Barnish, M., Robinson, S., Nikram, E., Bello, S., Dodman, S., Halpin, D. & Hoyle, M., 2018, University of Exeter. 223 p.Research output: Book/Report › Commissioned report › Research
Open Access
Brigatinib for treating ALK-positive non-small-cell lung cancer after crizotinib [ID1328]: A Single Technology Appraisal
Griffin, E., Barnish, M., Packman, D., Coelho, H., Matthews, J., Dodman, S., Robinson, S., Dangoor, A., Dorey, N. & Hoyle, M., 2018, University of Exeter. 189 p.Research output: Book/Report › Commissioned report › Research
Open Access
2017
Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma: A Single Technology Appraisal
Tikhonova, I., Jones-Hughes, T., Dunham, J., Warren, F., Robinson, S., Stephens, P. & Hoyle, M., 2017, University of Exeter. 167 p.Research output: Book/Report › Commissioned report › Research
Open Access
Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours: A Single Technology Appraisal
Jones-Hughes, T., Dunham, J., Robinson, S., Napier, M. & Hoyle, M., 2017, University of Exeter. 142 p.Research output: Book/Report › Commissioned report › Research
Open Access
2016
Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts: A Single Technology Appraisal
Mujica Mota, R., Varley-Campbell, J., Tikhonova, I., Cooper, C., Hoyle, M., Rudin, C. & Snowsill, T., 2016, University of Exeter. 145 p.Research output: Book/Report › Commissioned report › Research
Open Access
Everolimus, lutetium-177 DOTATATE and sunitinib for treating unresectable or metastatic neuroendocrine tumours with disease progression
Varley-Campbell, J., Mujica Mota, R., Tikhonova, I., Cooper, C., Griffin, E., Haasova, M., Peters, J., Lucherini, S., Talens-Bou, J., Long, L., Sherriff, D., Napier, M., Ramage, J. & Hoyle, M., 2016, University of Exeter. 372 p.Research output: Book/Report › Commissioned report › Research
Open Access
Lutetium
Neuroendocrine Tumors
Disease Progression
Cost-Benefit Analysis
Quality-Adjusted Life Years
The clinical and cost-effectiveness of lenalidomide for people who have received at least one prior therapy with bortezomib (partial review of TA171): A critique of the submission from Celgene. Addendum
Huxley, N., Long, L., Briscoe, S. & Hoyle, M., 2016, University of Exeter. 54 p.Research output: Book/Report › Commissioned report › Research
Open Access
2015
Cetuximab (review of TA176) and panitumumab (partial review of TA240) for the first line treatment of metastatic colorectal cancer [ID794]: Multiple Technology Appraisal (MTA)
Huxley, N., Crathorne, L., Varley-Campbell, J., Tikhonova, I., Snowsill, T., Briscoe, S., Peters, J., Bond, M., Napier, M. & Hoyle, M., 2015, University of Exeter. 24 p.Research output: Book/Report › Commissioned report › Research
Open Access
Immunosuppressive therapy for kidney transplantation in adults (review of technology appraisal guidance 85): A systematic review and economic model
Jones-Hughes, T., Snowsill, T., Haasova, M., Coelho, H., Crathorne, L., Cooper, C., Mujica-Mota, R., Peters, J., Varley-Campbell, J., Huxley, N., Moore, J., Allwood, M., Lowe, J., Hyde, C., Hoyle, M., Bond, M. & Anderson, R., 2015, University of Exeter. 759 p.Research output: Book/Report › Commissioned report › Research
Open Access
2014
Obinutuzumab in combination with chlorambucil for previously untreated chronic lymphocytic leukaemia: a critique of the submission from Roche
Hoyle, M., Long, L., Huxley, N., Crathorne, L., Briscoe, S. & Rudin, C., 2014, University of Exeter. 190 p.Research output: Book/Report › Commissioned report › Research
Open Access
2013
Bosutinib for previously treated chronic myeloid leukaemia: a single technology appraisal
Hoyle, M., Snowsill, T., Haasova, M., Cooper, C. & Rudin, C., 2013, University of Exeter. 304 p.Research output: Book/Report › Commissioned report › Research
Open Access
2011
Dasatinib, nilotinib, and standard dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses
Hoyle, M., Pavey, T., Ciani, O., Crathorne, L., Jones-Hughes, T., Cooper, C., Osipenko, L., Venkatachalam, M., Rudin, C., Ukoumunne, O., Garside, R. & Anderson, R., 2011, University of Exeter. 242 p.Research output: Book/Report › Commissioned report › Research
Open Access
The effectiveness and cost effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal 150 and part review of technology appraisal 118): a systematic review and economic model
Hoyle, M., Crathorne, L., Peters, J., Jones-Hughes, T., Cooper, C., Napier, M., Tappenden, P. & Hyde, C., 2011, University of Exeter. 214 p.Research output: Book/Report › Commissioned report › Research
Open Access
2010
Bendamustine for the first-line treatment of chronic lymphocytic leukaemia (Binet stage B or C) in patients for whom fludarabine combination chemotherapy is not appropriate: a critique of the submission from Napp
Hoyle, M., Crathorne, L., Jones-Hughes, T. & Stein, K., 2010, University of Exeter. 125 p.Research output: Book/Report › Commissioned report › Research
Open Access
The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease (review of TA111): a systematic review and economic model
Bond, M., Rogers, G., Peters, J., Anderson, R., Hoyle, M., Miners, A., Moxham, T., Davis, S., Thokala, P., Wailoo, A., Jeffreys, M. & Hyde, C., 2010, University of Exeter. 403 p.Research output: Book/Report › Commissioned report › Research
Open Access
2009
The clinical and cost-effectiveness of sunitinib for the treatment of gastrointestinal stromal tumours: a critique of the submission from Pfizer
Bond, M., Hoyle, M., Moxham, T., Napier, M. & Anderson, R., 2009, University of Exeter. 101 p.Research output: Book/Report › Commissioned report › Research
Open Access
2008
Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation
Thompson-Coon, J., Hoyle, M., Green, C., Liu, Z., Welch, K., Moxham, T. & Stein, K., 2008, University of Exeter. 307 p.Research output: Book/Report › Commissioned report › Research
Open Access
The clinical- and cost-effectiveness of lenalidomide for multiple myeloma in people who have received at least one prior therapy: an evidence review of the submission from Celgene
Hoyle, M., Rogers, G., Garside, R., Moxham, T. & Stein, K., 2008, University of Exeter. 124 p.Research output: Book/Report › Commissioned report › Research
Open Access